On Tuesday, Adaptimmune Therapeutics Plc ADR (NASDAQ: ADAP) was 3.69% up from the session before settling in for the closing price of $0.55. A 52-week range for ADAP has been $0.53 – $2.05.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales surged by 193.13% over the last five years. When this article was written, the company’s average yearly earnings per share was at 71.06%. With a float of $226.47 million, this company’s outstanding shares have now reached $255.70 million.
The firm has a total of 449 workers. Let’s measure their productivity. In terms of profitability, gross margin is 95.26%, operating margin of -28.14%, and the pretax margin is -28.42%.
Adaptimmune Therapeutics Plc ADR (ADAP) Breakdown of a Key Holders of the stock
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Adaptimmune Therapeutics Plc ADR stocks. The insider ownership of Adaptimmune Therapeutics Plc ADR is 11.49%, while institutional ownership is 37.29%. The most recent insider transaction that took place on Jan 17 ’25, was worth 3,243. In this transaction Chief Medical Officer of this company sold 5,584 shares at a rate of $0.58, taking the stock ownership to the 7,510 shares. Before that another transaction happened on Jan 17 ’25, when Company’s Chief Patient Supply Officer sold 5,584 for $0.58, making the entire transaction worth $3,243. This insider now owns 7,510 shares in total.
Adaptimmune Therapeutics Plc ADR (ADAP) Recent Fiscal highlights
Wall Street market experts anticipate that the next fiscal year will bring earnings of 0 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 71.06% per share during the next fiscal year.
Adaptimmune Therapeutics Plc ADR (NASDAQ: ADAP) Trading Performance Indicators
You can see what Adaptimmune Therapeutics Plc ADR (ADAP) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 3.82. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 0.83.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.21, a number that is poised to hit -0.03 in the next quarter and is forecasted to reach -0.08 in one year’s time.
Technical Analysis of Adaptimmune Therapeutics Plc ADR (ADAP)
Analysing the last 5-days average volume posted by the [Adaptimmune Therapeutics Plc ADR, ADAP], we can find that recorded value of 1.13 million was better than the volume posted last year of 1.03 million. As of the previous 9 days, the stock’s Stochastic %D was 30.06%. Additionally, its Average True Range was 0.04.
During the past 100 days, Adaptimmune Therapeutics Plc ADR’s (ADAP) raw stochastic average was set at 11.83%, which indicates a significant decrease from 51.83% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 37.72% in the past 14 days, which was lower than the 70.72% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $0.5924, while its 200-day Moving Average is $0.8892. Now, the first resistance to watch is $0.5998. This is followed by the second major resistance level at $0.6271. The third major resistance level sits at $0.6669. If the price goes on to break the first support level at $0.5327, it is likely to go to the next support level at $0.4929. Now, if the price goes above the second support level, the third support stands at $0.4656.
Adaptimmune Therapeutics Plc ADR (NASDAQ: ADAP) Key Stats
There are 255,883K outstanding shares of the company, which has a market capitalization of 146.52 million. As of now, sales total 60,280 K while income totals -113,870 K. Its latest quarter income was 40,900 K while its last quarter net income were -17,620 K.
